Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms San Diego, CA, July 2025- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL® turbo and fPELA® turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the
Continue Reading
- Products & Solutions
- FDA IVD
- About Us
- News & Events
- Contact
- Additional Sites